Evaluation and management of acute high-grade immunotherapy-related neurotoxicity

Heliyon. 2023 Feb 14;9(3):e13725. doi: 10.1016/j.heliyon.2023.e13725. eCollection 2023 Mar.

Abstract

Immune checkpoint inhibitor monoclonal antibodies allow the host's immune system to attack tumors, which has revolutionized cancer care over the last decade. As the use of immune checkpoint inhibitors has expanded, so have autoimmune-like complications known as immune-related adverse events. These include the infrequent but increasingly more common, potentially deadly neurological immune related adverse events. When feeling acutely ill, patients will often seek care not from their oncologist but from their family physician, clinics, emergency, and urgent care sites, or other available providers. Thus, while assessing acutely ill cancer patients who are experiencing neurological symptoms, non-oncologists should be prepared to recognize, diagnose, and treat neurological immune related adverse events in addition to more familiar conditions. This narrative review is designed to update acute care clinicians on current knowledge and to present a symptom-based framework for evaluating and treating neurological immune related adverse events based on the leading immunotoxicity organizations' latest recommendations.

Keywords: Diagnosis; Emergency department; Immune checkpoint inhibitors; Immune-related adverse effects; Management; Nervous system.

Publication types

  • Review